Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 5:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Extraintestinal Pathogenic Escherichia Coli Prevention Clear all

Completed Phase 3 Interventional Accepts healthy volunteers

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

NCT04899336

View directory record Official record

Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Interventions: ExPEC9V, Placebo; Biological · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 60 Years and older

Enrollment: 17,935 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 142
States / cities: Guntersville, Alabama • Phoenix, Arizona • Sun City West, Arizona + 100 more

Source: ClinicalTrials.gov public record

Updated May 10, 2026 · Synced May 22, 2026, 5:05 AM EDT

Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health

NCT03819049

View directory record Official record

Conditions: Extraintestinal Pathogenic Escherichia Coli Prevention
Interventions: ExPEC10V, ExPEC4V, Prevnar 13, Placebo; Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 60 Years and older

Enrollment: 836 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 12
States / cities: Huntsville, Alabama • Melbourne, Florida • Miami, Florida + 9 more

Source: ClinicalTrials.gov public record

Updated May 10, 2026 · Synced May 22, 2026, 5:05 AM EDT

Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older

NCT06134804

View directory record Official record

Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Interventions: ExPEC9V, Placebo, HD quadrivalent influenza vaccine; Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 65 Years and older

Enrollment: 959 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 24
States / cities: Huntsville, Alabama • Mobile, Alabama • San Diego, California + 19 more

Source: ClinicalTrials.gov public record

Updated Apr 2, 2026 · Synced May 22, 2026, 5:05 AM EDT